Rejected at 7:13 p.m. Feb, 02, 2024 ] by herstein.jacob
Author: bkavin
Related Note: 1488847733019 2
Rationale for change

Better describes mechanism. Previous card could accidentally make someone thing its a GP11b antagonist when its not - its an ADP receptor antagonist.
Source: AMBOSS - https://next.amboss.com/us/article/Um0bUg?q=clopidogrel#Zb288dda860ff65493b01ea10fbf1e10c

Rejection reason

This is obvious because it is in the name of the drug - the card is asking what happens as a result of ADP receptor blockade

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#NinjaNerd::09_Hematology::01_Physiology::07_Hemostasis:_Coagulation_Cascade #AK_Step2_v12::#B&B::02_Cardio::02_Ischemic_Heart_Disease::02_STEMI::Extra #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::02_Bleeding_Disorders:_Platelet_Disorders_DDx #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::03_Physiology::04_Thrombogenesis #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::02_Platelet_Activation #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::08_Glycoprotein_IIb/IIIa_Inhibitors #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::19_Platelet_Disorders #AK_Other::Only_Step_1 #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::15_Antiplatelets,_Anticoagulants,_and_Thrombolytics #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::06_ADP_Receptor_Inhibitors #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::06_Platelets::05_Antiplatelet_Medications #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::01_Antiplatelet_Medications_(MOA,_Indications,_AR,_CI) #AK_Step1_v12::#UWorld::COMLEX::24937 #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::06_Antiplatelet_Drugs::Extra #AK_Step1_v12::#UWorld::Step::1828 #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::06_Antiplatelets::*ADP_receptor_Inhibitors #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::03_Antiplatelet_agents #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::04_Antiplatelet_Drugs::Extra #AK_Step2_v12::#SketchyIM::01_Cardiology::01_Ischemic_Heart_Disease::09_Post_ACS_Management #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::03_Mixing_Studies,_Ristocetin,_and_D-dimer #AK_Step1_v12::#AMBOSS::T-069i #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology